Filing Details

Accession Number:
0001077183-24-000013
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-20 16:32:59
Reporting Period:
2024-02-15
Accepted Time:
2024-02-20 16:32:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1077183 Neogenomics Inc NEO Services-Testing Laboratories (8734) 742897368
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1951869 C Alicia Olivo 9490 Neogenomics Way
Fort Myers FL 33912
General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-02-15 2,587 $14.96 34,866 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (Right to Buy) $19.12 2026-09-30 1,046 1,046 Direct
Common Stock Stock Option (Right to Buy) $27.34 2027-05-01 1,024 1,024 Direct
Common Stock Stock Option (Right to Buy) $48.99 2028-05-01 516 516 Direct
Common Stock Stock Option (Right to Buy) $46.10 2028-08-01 1,117 1,117 Direct
Common Stock Stock Option (Right to Buy) $9.45 2029-05-01 22,222 22,222 Direct
Common Stock Stock Option (Right to Buy) $10.05 2029-09-01 55,332 55,332 Direct
Common Stock Stock Option (Right to Buy) $19.65 2030-05-11 36,508 36,508 Direct
Common Stock Restricted Stock Unit $0.00 19,508 19,508 Direct
Common Stock Performance Stock Unit $0.00 2026-05-11 19,508 19,508 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2026-09-30 1,046 1,046 Direct
2027-05-01 1,024 1,024 Direct
2028-05-01 516 516 Direct
2028-08-01 1,117 1,117 Direct
2029-05-01 22,222 22,222 Direct
2029-09-01 55,332 55,332 Direct
2030-05-11 36,508 36,508 Direct
19,508 19,508 Direct
19,508 19,508 Direct
Footnotes
  1. This balance includes 313 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3.
  2. On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vested ratably over the first four anniversary dates of the grant date.
  3. On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  4. On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  5. On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  6. On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  7. On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  8. On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date.
  9. On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
  10. Once vested, the shares of common stock are not subject to expiration.
  11. On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.